JSPR INVESTOR ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In JSPR To Contact Him Directly To Discuss Their Options

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Jasper Therapeutics, Inc. due to allegations of violations of federal securities laws, particularly concerning misleading statements and lack of proper manufacturing controls [2][4]. Group 1: Legal Investigation - The firm is encouraging investors who suffered losses exceeding $75,000 in Jasper between November 30, 2023, and July 3, 2025, to discuss their legal options [1]. - A federal securities class action has been filed against Jasper, with a deadline of November 18, 2025, for investors to seek the role of lead plaintiff [2][6]. Group 2: Allegations Against Jasper - The complaint alleges that Jasper lacked necessary controls to ensure third-party manufacturers complied with current Good Manufacturing Practices (cGMP), which could confound study results and negatively impact product prospects [4]. - Specific issues were highlighted regarding the BEACON Study, where results were confounded by a problematic drug product lot, leading to a halt in development for certain studies and a need for cost-cutting measures [5]. Group 3: Financial Impact - Following the announcement of these issues, Jasper's stock price fell by $3.73 per share, or 55.1%, closing at $3.04 per share on July 7, 2025 [5].